Novo Nordisk

What Novo Nordisk does

Novo Nordisk A/S is a Denmark-headquartered (Bagsværd) global pharmaceutical company founded in 1923 that develops, manufactures, and commercializes peptide-based therapies for chronic metabolic and rare diseases. The company employs approximately 67,900 people across 80 countries and markets products in approximately 170 countries. It is publicly traded on Nasdaq Copenhagen (B shares) and NYSE (ADRs: NVO), and is majority-controlled by the Novo Nordisk Foundation (a non-profit foundation).

The company operates a portfolio-style pharmaceutical business anchored by the GLP-1 receptor agonist franchise built on semaglutide, including Wegovy (injection and the newly launched oral pill, 25 mg), Ozempic, Rybelsus, and Saxenda/liraglutide products. Its diabetes portfolio spans a full insulin range (Tresiba, Levemir, Awiqli/insulin icodec, Fiasp, NovoRapid, Ryzodeg, NovoMix), oral antidiabetics, and connected insulin pens (Biocorp-acquired). Adjacent franchises include haemophilia (NovoSeven, NovoEight, NovoThirteen, Esperoct, Refixia, Alhemo), growth hormone disorders (Norditropin, Sogroya), and women's health hormones. The R&D pipeline layers CagriSema (cagrilintide + semaglutide, NDA filed December 2025), zenagamtide, efruxifermin (acquired via $4.7B Akero deal, MASH), Ziltivekimab (cardiovascular), CDR132L, etavopivat, INV-202/Monlunabant, amycretin, and zaltenibart on top of the commercial franchise.

Novo Nordisk generates revenue primarily through branded prescription pharmaceutical sales under a unit-pricing model, dispensed via retail and hospital pharmacies (~170 countries), telehealth channel partners (Hims & Hers Health, Zealthy), and direct-to-consumer cash-pay platforms such as NovoCare. Strategic pricing actions include a $350/month temporary Wegovy introductory price in the U.S., $50/month Medicare Part D GLP-1 Bridge copay (from July 1, 2026), and planned 50%/35% WAC reductions for Wegovy and Ozempic effective January 1, 2027. The business also captures licensing/milestone revenue (e.g., $26.5M Q1 2026 from Septerna GPCR collaboration) and executes capital return programs (up to DKK 15B share repurchase initiated February 2026).

Name

Novo Nordisk

Legal name

Novo Nordisk A/S

Website

https://novonordisk.com

Company type

Public

Founded year

1923

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Novo Nordisk is a Denmark-headquartered global pharmaceutical company that develops and commercializes peptide-based therapies for diabetes, obesity, MASH, cardiovascular, haemophilia, and rare endocrine diseases, anchored by the GLP-1 franchise (Wegovy, Ozempic, Rybelsus) and serving patients in approximately 170 countries.

Ownership category

akta.pro rank

Product category

Diabetes and obesity pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE)

akta.pro secondary industry

Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ)

Keywords

• Diabetes pharmaceuticals
• Obesity medications
• GLP-1 receptor agonists
• Insulin therapies
• Peptide therapeutics

Headquarters

HQ city

Bagsværd

HQ country

Denmark

HQ region

Europe

Offices9 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Supply Chain, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Branded prescription pharmaceutical sales: Predominantly unit-pricing revenue from sale of approved finished-dose medicines (Wegovy injection and pill, Ozempic, Rybelsus, Saxenda, insulin portfolio incl. Tresiba/Insulatard/Awiqli, haemophilia franchise, growth hormone Norditropin/Sogroya) dispensed through pharmacies, hospitals, and telehealth partners across ~170 countries.
2. Drug delivery device sales: Sales of durable and disposable prefilled insulin pens, needles, cartridges, and smart connected pens (acquired Biocorp device platform), sold alongside or bundled with pharmaceutical prescriptions.
3. Share repurchase / capital return programme: Up to DKK 15 billion 12-month share repurchase programme executed under EU MAR Safe Harbour rules (initiated 4 February 2026; additional tranche 6 May 2026); ~DKK 5.27 billion executed by mid-June 2026, with 20.96 million B shares repurchased since February 2026.
4. Out-licensed pipeline assets and milestone payments: Licensing and milestone revenue from collaboration partners such as Omeros (zaltenibart licensing deal) and Septerna (GPCR collaboration producing $26.5M Q1 2026 collaboration revenue).

Pricing tiers

Go-to-market motion5 records

Distribution channels7 records

Marketing channels11 records

Core offering

Novo Nordisk is a global pharmaceutical manufacturer that develops, produces, and distributes prescription medicines for serious chronic diseases. Its commercial portfolio is anchored by the semaglutide GLP-1 franchise (Wegovy injection and oral pill for chronic weight management and cardiovascular risk reduction, Ozempic and Rybelsus for type 2 diabetes), a comprehensive insulin portfolio (Tresiba, Levemir, Awiqli, Xultophy, Fiasp, NovoRapid, Ryzodeg, NovoMix), a haemophilia range (NovoSeven, NovoEight, Esperoct, Refixia, Alhemo), growth hormone therapy (Norditropin, Sogroya), and women's hormone replacement products, sold across approximately 170 countries through retail and hospital pharmacies, telehealth partners, and direct cash-pay channels.

Product overview

Novo Nordisk is a global pharmaceutical company offering a broad, portfolio-style set of products rather than a single unified SaaS-style platform. Its commercial portfolio is anchored by the GLP-1 franchise (Wegovy injection and the newly launched Wegovy pill, Ozempic, Rybelsus oral semaglutide, Saxenda and Victoza liraglutide) for obesity and type 2 diabetes, alongside a full diabetes portfolio spanning once-weekly Awiqli (insulin icodec), long-acting Tresiba, Levemir and Xultophy, intermediate-acting Insulatard, short-acting Actrapid, fast-acting Fiasp and NovoRapid, premix Ryzodeg and NovoMix and Mixtard, oral antidiabetic NovoNorm (repaglinide), and GlucaGen glucagon. The haemophilia portfolio includes NovoSeven, NovoEight, NovoThirteen, Refixia, Esperoct and Alhemo (concizumab). Growth disorders are addressed with Norditropin and once-weekly Sogroya, and women's health with Vagifem, Activelle, Kliogest, Novofem, Trisequens and Estrofem. The pipeline layers investigational therapies on top: CagriSema (cagrilintide + semaglutide, REDEFINE and REIMAGINE programs), zenagamtide, amycretin, efruxifermin (acquired via Akero for MASH), Ziltivekimab across ASCVD/HFpEF/AMI, Coramitug, etavopivat for sickle cell disease, CDR132L from Cardior, INV-202 from Inversago, and zaltenibart licensed from Omeros, plus filed assets Icosema, insulin icodec, semaglutide 7.2 mg and Denecimig. Supporting these medicines are Novo Nordisk's pre-filled and smart connected pen devices (including technology from the Biocorp acquisition), the NovoCare patient support platform, and the NovoTrials clinical trial data access portal for researchers. Novo Nordisk also disclosed an IT security incident on June 11, 2026, and is applying AI (including via an OpenAI partnership) across drug development, manufacturing, and supply chain operations.

Differentiator

Problem solved

Functional benefit

Brands

• Wegovy®: Semaglutide for chronic weight management (once-weekly injection and once-daily oral pill)
• Ozempic®
• Rybelsus®
• Saxenda®
• Victoza®
• Awiqli®
• Tresiba®
• Xultophy®
• Levemir®
• Fiasp®
• NovoRapid®
• NovoNorm®
• NovoSeven®
• NovoEight®
• NovoThirteen®
• Esperoct®
• Refixia®
• Alhemo®
• Norditropin®
• Sogroya®
• GlucaGen®
• Ryzodeg®

Products and services

• Wegovy (semaglutide injection and oral pill) GLP-1 receptor agonist approved for chronic weight management in adults (and adolescents 12+ for the injection) with obesity or overweight and at least one weight-related comorbidity, and to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and obesity/overweight. Available as once-weekly subcutaneous injection (2.4 mg, 7.2 mg) and as a once-daily oral tablet (Wegovy pill, 25 mg) with ~17% mean weight loss in OASIS 4.
• Ozempic (semaglutide) Once-weekly subcutaneous GLP-1 receptor agonist indicated for the treatment of adults with type 2 diabetes mellitus; also widely used off-label and via approved label expansions for weight management. The active ingredient semaglutide is the same as in Wegovy and Rybelsus.
• Rybelsus (oral semaglutide) World's first oral GLP-1 receptor agonist for the treatment of adults with type 2 diabetes mellitus, taken as a once-daily tablet using SNAC-enabled absorption technology.
• Saxenda (liraglutide 3 mg) Once-daily subcutaneous GLP-1 receptor agonist (liraglutide 3 mg) approved for chronic weight management in adults with obesity or overweight with weight-related comorbidities.
• Victoza (liraglutide) Once-daily subcutaneous GLP-1 receptor agonist (liraglutide) for the treatment of type 2 diabetes mellitus in adults, adolescents, and children aged 10 years and older.
• Awiqli (insulin icodec) Once-weekly basal insulin for the treatment of diabetes mellitus in adults.
• Tresiba (insulin degludec) Long-acting basal insulin (insulin degludec) for the treatment of diabetes mellitus in adults, adolescents, and children aged 1 year and older.
• Xultophy (insulin degludec/liraglutide) Fixed-ratio combination of insulin degludec and liraglutide for once-daily subcutaneous treatment of type 2 diabetes mellitus in adults (approved in the US as Xultophy 100/3.6).
• Levemir (insulin detemir) Long-acting basal insulin (insulin detemir) for the treatment of diabetes mellitus in adults, adolescents, and children aged 2 years and older.
• Fiasp (insulin aspart) Fast-acting mealtime insulin (insulin aspart) for the treatment of diabetes mellitus in adults, adolescents, and children aged 1 year and older.
• NovoRapid (insulin aspart) Fast-acting mealtime insulin (insulin aspart) for the treatment of diabetes mellitus; known as NovoLog in the United States. Also supplied as NovoRapid PumpCart pre-filled cartridges for insulin pumps.
• NovoNorm (repaglinide) Oral meglitinide (repaglinide) for the treatment of adults with type 2 diabetes mellitus.
• GlucaGen (glucagon) Glucagon for the treatment of severe hypoglycemic episodes in adults, adolescents, and children with diabetes mellitus.
• NovoSeven (recombinant factor VIIa) Recombinant coagulation factor VIIa for the treatment of bleeding episodes and prevention of bleeding during surgery in patients with haemophilia A or B with inhibitors, acquired haemophilia, congenital factor VII deficiency, or Glanzmann's thrombasthenia.
• NovoEight (recombinant factor VIII) Recombinant coagulation factor VIII for the treatment and prophylaxis of bleeding in patients with haemophilia A (known as Novoeight in the US).
• Esperoct (turoctocog alfa pegol) PEGylated recombinant coagulation factor VIII (turoctocog alfa pegol) for the treatment and prophylaxis of bleeding in patients with haemophilia A.
• Refixia (nonacog beta pegol) PEGylated recombinant coagulation factor IX (nonacog beta pegol) for the treatment and prophylaxis of bleeding in patients with haemophilia B (approved in the US as REBINYN).
• Alhemo (concizumab-mtci) Anti-tissue factor pathway inhibitor (anti-TFPI) monoclonal antibody (concizumab) for routine prophylaxis to prevent or reduce bleeding episodes in patients with haemophilia A or B with inhibitors.
• Norditropin (somatropin) Recombinant human growth hormone (somatropin) for the treatment of growth disorders in children and growth hormone deficiency in adults.
• Sogroya (somapacitan) Once-weekly long-acting growth hormone derivative (somapacitan) for the treatment of growth hormone deficiency in adults and children aged 3 years and older.
• Novo Nordisk connected and pre-filled insulin pen devices Broad range of disposable pre-filled pens, durable pens with replaceable insulin cartridges, and smart connected pens and apps (Biocorp-acquired) for diabetes and obesity treatment, supporting dose tracking and adherence.

Quantifiable outcome

• Wegovy pill: ~17% mean weight loss (on-treatment) in OASIS 4; ~13.6% in treatment-policy estimand
• +6 more outcomes

Named customers4 records

Segments10 records

Ideal customer profiles5 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration3 records

AI capability3 records

Feature7 records

Partnerships

25 partnerships are on record, tiered minor, core and flagship.

• Dubai government delegation / Maersk / Healthcare Denmark / Creative DenmarkminorStrategic or Co-development Partner · 25 June 2026Hosted Dubai government delegation in Copenhagen in June 2026 to discuss cooperation in logistics, healthcare, education, urban planning and creative industries as Dubai advances its trade and innovation ambitions; relationship supports UAE market entry for Wegovy pill.
• Bloomberg PhilanthropiesminorStrategic or Co-development Partner · 25 June 2026Earthshot Prize Impact Assembly context — Bloomberg Philanthropies announced $260 million investment to expand the Bloomberg Ocean Initiative; Novo Nordisk is an Earthshot partner. Supports shared sustainability and ocean protection goals.
• re.greencoreStrategic or Co-development Partner · 24 June 202620-year partnership to restore 500 hectares of Amazonian forest in Paragominas municipality of Pará, Brazil. Expected to generate 87,000 carbon dioxide removal credits through natural regeneration and active planting of native species, with sustainable timber management on up to 30% of the area. First CDR credit issuance expected November 2031; third-party verification every three years through 2045. Highlighted in Earthshot Prize Impact Assembly.
• ZealthyminorChannel Partner/ Reseller/ Distributor · 23 June 2026New York-based telehealth platform offering online Ozempic evaluations, insurance coordination, and prescription management for type 2 diabetes patients; charges $39 introductory then $135/month membership. Provides prior-authorization assistance to access Ozempic for ~$25/month with qualifying insurance.
• WalmartcoreChannel Partner/ Reseller/ Distributor · 22 June 2026Announced clinical support services to help Medicare beneficiaries navigate the GLP-1 Bridge program's prior-authorization requirements and eligibility rules alongside CVS Health.
• 340B Health / American Hospital AssociationminorOthers · 22 June 2026Novo Nordisk reportedly implementing data-sharing requirements in 340B drug pricing programme for safety-net hospitals; hospital lobbies including 340B Health and AHA urging federal regulators to overturn similar Eli Lilly precedent.
• BioInnovation Institute (BII)coreStrategic or Co-development Partner · 19 June 2026Novo Nordisk Foundation-funded entity managing the CardioMetabolic Bridge pan-European research programme; DKK 450 million ($69.1 million) committed over six years for obesity, type 2 diabetes, and cardiometabolic disease research with first lab opening in London and sister sites in Italy and Germany. Operates the Foundation's BioInnovation Hub in Cambridge, Massachusetts for biotech collaboration.
• CignacoreOthers · 18 June 2026Major health insurer planning to drop GLP-1 weight loss coverage (Wegovy and Zepbound) effective July 1, 2026, citing increased availability and evolving treatment options; represents both a market access challenge and a payer-relations touchpoint for Novo Nordisk.
• Forbion (European biotech venture fund)minorOthers · 16 June 2026Novo Nordisk's long-time Head of M&A John McDonald joined Forbion's Boston office as operating partner; demonstrates talent and capital flow between Novo Nordisk's corporate development function and the European biotech ecosystem.
• Viking TherapeuticsminorOthers · 1 April 2026Viking Therapeutics positioned as a potential challenger to the Novo Nordisk / Eli Lilly duopoly with VK2735 Phase 2 data showing up to 14.7% weight loss injectable and 12.2% oral; Phase 3 VK2735 data not expected until 2027.
• Hims & Hers Health (HIMS)flagshipChannel Partner/ Reseller/ Distributor · 1 March 2026Distribution partnership announced March 2026 enabling HIMS to dispense branded Wegovy and Ozempic on its telehealth platform. Renewed after resolving a prior legal dispute over compounded GLP-1 products. Barclays raised HIMS price target to $39 (from $29) citing 35% YoY website traffic growth and 21% MoY monthly active user growth tied to this partnership; weight-loss business represents ~one-third of HIMS revenue.
• Peer AIcoreTechnology or Integration · 1 January 2026San Francisco-based startup whose predictive regulatory intelligence platform analyses historical FDA decisions to predict queries and weak points in approval submissions; Novo Nordisk actively exploring similar AI tools to streamline regulatory processes.
• Omeros CorporationcoreOEM/ Whitelabel/ Licensing Partner · 1 January 2026Asset purchase and licensing agreement under which Novo Nordisk acquired global rights to zaltenibart (Phase 2 complement inhibitor); generates upfront payments to Omeros contributing to its $56.06 million Q1 2026 net income. Listed in Novo Nordisk R&D pipeline as Phase 2 'Zaltenibart'.
• Biocon Ltd.coreStrategic or Co-development Partner · 1 January 2026Cristália filed for ANVISA registration in partnership with India's Biocon for generic semaglutide; broader Biocon positioning as the world's top insulin supplier within five years capitalizes on Big Pharma shift to GLP-1 drugs, creating a potential competitive channel for Novo Nordisk's diabetes portfolio.
• Akero TherapeuticsflagshipStrategic or Co-development Partner · 9 December 2025Completed acquisition of Akero Therapeutics for $4.7 billion cash plus contingent $0.5 billion tied to regulatory approval of efruxifermin (EFX) for MASH; delisted from Nasdaq. Adds Phase 3 'Efruxifermin in MASH' to Novo Nordisk R&D pipeline and expands metabolic-disease portfolio alongside semaglutide.
• CVS HealthflagshipChannel Partner/ Reseller/ Distributor · 11 October 2025Expanded GLP-1 support initiatives including $50 monthly copay program for eligible Medicare patients and virtual weight-management consultations at $49 per visit through MinuteClinic; key channel for Medicare Part D Bridge program launched July 1, 2026.
• Copenhagen Competitiveness Summit / European CommissioncoreStrategic or Co-development Partner · 1 October 2025Co-signatory of the Copenhagen Pledge alongside Airbus, Siemens, SAP, Thales, Saab and other European leaders committing to increase European investments by an average of 50% by 2030, conditional on policy reforms from European policymakers.
• Septerna, Inc. (SEPN)coreStrategic or Co-development Partner · 1 January 2025GPCR drug discovery collaboration driving $26.5 million in Q1 2026 collaboration revenue (up from $0.2 million YoY); contributes to Septerna's $522.1 million cash balance and runway into mid-2029. Lead candidates include SEP-631 (Phase 2-ready chronic urticaria) and SEP-479 (Phase 1 hypoparathyroidism).
• NovavaxcoreOEM/ Whitelabel/ Licensing Partner · 1 November 2024Acquired Czech Republic manufacturing plant from Novavax for $200 million 18 months prior to its June 17, 2026 opening; subsequently invested $168 million to repurpose facility for supportive proteins used in next-generation diabetes and obesity treatments (300 employees; one of seven global manufacturing hubs).
• Cardior PharmaceuticalscoreStrategic or Co-development Partner · 25 March 2024Acquired Germany-based Cardior Pharmaceuticals for over €1 billion to expand into cardiovascular disease; deal includes Phase 2 antisense oligonucleotide CDR132L designed to treat heart failure and prevent heart failure progression (listed in Novo Nordisk R&D pipeline as Phase 2 'CDR132L').
• OpenAIflagshipTechnology or Integration · 1 January 2024Strategic AI collaboration to apply generative AI across drug development, manufacturing, and supply chain operations. Cited by Motley Fool and analyst reports as a key differentiator versus Big Tech AI exposure in healthcare; complements Novo Nordisk Foundation's CardioMetabolic Bridge research network.
• Biocorp (drug delivery device maker)coreOEM/ Whitelabel/ Licensing Partner · 11 October 2023Acquired all shares of France-based Biocorp to expand connected device and smart pen capabilities; complements the 'Smart Pens, Devices and Apps' product line. Provides foundation for the smart insulin delivery platform cited in Novo Nordisk's diabetes digital strategy.
• Inversago Pharma Inc.coreStrategic or Co-development Partner · 8 September 2023Completed acquisition for up to $1.075 billion depending on milestone achievements; deal included INV-202, an oral CB1 inverse agonist for obesity, diabetes and metabolic disorders (Phase 2 at acquisition). Foundation for subsequent 'Monlunabant' pipeline candidate.
• Forma TherapeuticscoreStrategic or Co-development Partner · 1 September 2022Acquired for $1.1 billion all-cash to expand portfolio in sickle cell disease and rare blood disorders; included etavopivat in Phase 2/3 trials, which remains in Novo Nordisk R&D pipeline as Phase 2 'Etavopivat' and Phase 3 'Etavopivat (Sickle Cell Disease)'.
• Dicerna PharmaceuticalscoreStrategic or Co-development Partner · 28 December 2021Acquired for $3.3 billion ($38.25/share) and merged into Novo Nordisk as wholly-owned subsidiary, delisting from Nasdaq; brought GalXC RNA interference platform and renewed interest in RNAi drugs. Underpins siRNA GalXC-GYS2 and other metabolic assets.

Scale indicators14 records

Recent moves9 records

Expansion highlights7 records

Direct peers

• Eli Lilly and Company: Direct duopoly competitor in GLP-1 obesity/diabetes (Mounjaro/Zepbound/orforglipron/Foundayo). Both companies target the same obesity and T2D patient populations with injectable and oral GLP-1 therapies and are competing on AI-engine citation share, pipeline breadth (MASH, cardiovascular) and manufacturing capacity.

Broad incumbents

• Pfizer: Large incumbent pharmaceutical peer also navigating the $236-300B patent cliff and redirecting capital toward metabolic and cardiometabolic growth areas. Comparable in scale, multi-indication pipeline strategy and global commercial reach but does not have a leading GLP-1 franchise.
• Sanofi: Diabetes incumbent (Lantus, Toujeo, Soliqua) and rare disease player, recently expanding into obesity. Overlaps with Novo Nordisk in insulin, GLP-1 combinations and rare blood disorders, and serves similar HCP channels globally.
• Merck & Co. Broad incumbent pharma comparable in R&D scale, capital return programmes and recent M&A activity. Differs in therapeutic mix (oncology-heavy) but faces the same macro pressures of patent cliffs and need to redirect capital to cardiometabolic growth.
• AstraZeneca: Global pharma incumbent with overlapping cardiometabolic and rare disease franchises (Forxiga in T2D, Alexion rare disease unit). Comparable in scale, capital intensity, and need to defend franchises against GLP-1 class cannibalization.
• Roche: Swiss-headquartered pharma incumbent with comparable R&D scale, biologics manufacturing footprint and diabetes adjacency. Serves similar HCP and payer channels across ~170 countries and is similarly navigating biosimilar and generic pressures.
• Novartis: European-headquartered pharma incumbent with comparable global commercial footprint, capital return programme and recent restructuring activity. Overlaps in cardiovascular and rare disease but lacks a competitive obesity franchise.
• Amgen: Biologics-focused pharma incumbent comparable in capital intensity, M&A activity (Horizon) and pipeline diversification. Operates in cardiometabolic and rare disease adjacencies and is pursuing obesity programs.
• Boehringer Ingelheim: Private global pharma incumbent with direct overlap in diabetes (Trajenta/Jardiance family via Lilly alliance) and cardiometabolic disease. Comparable in manufacturing footprint, geographic reach and long-cycle R&D model.

Emerging players

• Viking Therapeutics: Emerging U.S. biotech with Phase 2 VK2735 data showing 14.7% injectable and 12.2% oral weight loss, positioning as a credible third entrant into the GLP-1 duopoly. Comparable in obesity mechanism focus but years behind on commercial scale.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat8 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xx.com/novonordisk
• YouTubeyoutube.com/user/novonordisk
• Facebookfacebook.com/novonordisk
• LinkedInlinkedin.com/company/novo-nordisk
• Instagraminstagram.com/novonordisk
• TikToktiktok.com/@novonordisk

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Subsidiaries6 records

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A16 records

Investments22 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Novo Nordisk